We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Imaging Agent to Drive Step-Change for Brain Cancer Imaging

By MedImaging International staff writers
Posted on 06 Nov 2024
Print article
Image: The Pixclara PET imaging agent for glioma could provide patients with greater diagnostic clarity (Photo courtesy of Telix)
Image: The Pixclara PET imaging agent for glioma could provide patients with greater diagnostic clarity (Photo courtesy of Telix)

Gliomas are highly diffusely infiltrative tumors that impact the surrounding brain tissue. They represent the most prevalent type of central nervous system (CNS) neoplasm originating from glial cells, accounting for around 30% of all brain and CNS tumors and approximately 80% of malignant brain tumors. There is a significant unmet need to enhance the diagnosis and management of gliomas, particularly after treatment. Traditional MRI imaging techniques have various limitations, such as a lack of biological specificity, reliance on the disruption of the blood-brain barrier, and an intrinsic inability to distinguish between tumor progression and treatment-related changes. These issues can lead to inconclusive results, delaying critical treatment decisions. With low survival rates and the necessity for prompt actions, precision imaging becomes essential. Now, a new PET imaging agent for gliomas has the potential to meet this need, providing patients with clearer diagnoses and aiding treatment decision-making.

Telix Pharmaceuticals (Melbourne, Australia) has developed Pixclara (18F-floretyrosine or 18F-FET), a PET agent designed to differentiate between progressive or recurrent gliomas and treatment-related changes in both adult and pediatric patients. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara), an imaging agent for gliomas. This application has been given priority review status, with a Prescription Drug User Fee Act (PDUFA) goal date set for April 26, 2025, facilitating a potential U.S. commercial launch in 2025.

While FET PET is already part of international clinical practice guidelines for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent available for adult and pediatric brain cancer imaging in the U.S. Given its potential to fulfill a significant medical need, Pixclara has been designated as an orphan drug and granted fast track designation by the FDA. Telix is also exploring the possibility of using Pixclara as a companion diagnostic agent for TLX101-Tx, an investigational neuro-oncology drug in development that targets the same amino acid transporter mechanism with therapeutic radiation.

“Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the U.S., and bring it into line with a more advanced standard of care currently used in other markets,” said Kevin Richardson, Chief Executive Officer, Telix Precision Medicine. “There is currently a critical need for better imaging in brain cancer, and Telix is dedicated to delivering precision medicine solutions that address patient needs and enhance both cancer imaging and treatment outcomes.”

Related Links:
Telix Pharmaceuticals

New
Gold Member
X-Ray QA Meter
T3 AD Pro
CT Detector
PURE INSIGHT
New
Imaging Table
CFPM201
New
Ultra-Flat DR Detector
meX+1717SCC

Print article
Radcal

Channels

Radiography

view channel
Image: The CT scanner prototype eliminates the need for physical compression of the breast (Photo courtesy of Quion Lowe and Lisa Dahm/U of A Cancer Center)

Novel Breast Cancer Screening Technology Could Offer Superior Alternative to Mammogram

Breast cancer represents 15.5% of new cancer cases and 7% of cancer-related deaths in the United States. Approximately 13.1% of women will be diagnosed with breast cancer during their lifetime.... Read more

Ultrasound

view channel
Image: Wearable ultrasound device offers continuous, long-term monitoring of muscle activity (Photo courtesy of Muyang Lin/UC San Diego)

Wearable Ultrasound Device Provides Long-Term, Wireless Muscle Monitoring

Electromyography (EMG) is the current clinical standard for monitoring muscle activity, utilizing metal electrodes placed on the skin to capture electrical signals from muscles. Despite its long-standing... Read more

General/Advanced Imaging

view channel
Image: Heavy smokers can ben Image (2):	efit from lung cancer screening using low-dose CT (Photo courtesy of 123RF)

Low-Dose CT Screening for Lung Cancer Can Benefit Heavy Smokers

Lung cancer is often diagnosed at a late stage, with only about one-fifth to one-sixth of patients surviving five years after diagnosis. A new report now suggests that low-dose computed tomography (CT)... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The advocacy partnership aims to help accelerate access to life-saving treatments (Photo courtesy of Philips)

Philips and Medtronic Partner on Stroke Care

A stroke is typically an acute incident primarily caused by a blockage in a brain blood vessel, which disrupts the adequate blood supply to brain tissue and results in the permanent loss of brain cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.